1. Home
  2. URGN vs PDEX Comparison

URGN vs PDEX Comparison

Compare URGN & PDEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • URGN
  • PDEX
  • Stock Information
  • Founded
  • URGN 2004
  • PDEX 1978
  • Country
  • URGN United States
  • PDEX United States
  • Employees
  • URGN N/A
  • PDEX N/A
  • Industry
  • URGN Biotechnology: Pharmaceutical Preparations
  • PDEX Medical/Dental Instruments
  • Sector
  • URGN Health Care
  • PDEX Health Care
  • Exchange
  • URGN Nasdaq
  • PDEX Nasdaq
  • Market Cap
  • URGN 831.6M
  • PDEX 167.6M
  • IPO Year
  • URGN 2017
  • PDEX N/A
  • Fundamental
  • Price
  • URGN $18.90
  • PDEX $51.52
  • Analyst Decision
  • URGN Strong Buy
  • PDEX Strong Buy
  • Analyst Count
  • URGN 8
  • PDEX 1
  • Target Price
  • URGN $29.00
  • PDEX $56.00
  • AVG Volume (30 Days)
  • URGN 1.3M
  • PDEX 50.9K
  • Earning Date
  • URGN 08-07-2025
  • PDEX 09-04-2025
  • Dividend Yield
  • URGN N/A
  • PDEX N/A
  • EPS Growth
  • URGN N/A
  • PDEX 379.10
  • EPS
  • URGN N/A
  • PDEX 2.76
  • Revenue
  • URGN $91,871,000.00
  • PDEX $64,123,999.00
  • Revenue This Year
  • URGN $39.80
  • PDEX $26.92
  • Revenue Next Year
  • URGN $108.94
  • PDEX $4.48
  • P/E Ratio
  • URGN N/A
  • PDEX $18.94
  • Revenue Growth
  • URGN 8.98
  • PDEX 29.65
  • 52 Week Low
  • URGN $3.42
  • PDEX $17.81
  • 52 Week High
  • URGN $19.36
  • PDEX $70.26
  • Technical
  • Relative Strength Index (RSI)
  • URGN 75.30
  • PDEX 60.84
  • Support Level
  • URGN $17.68
  • PDEX $48.71
  • Resistance Level
  • URGN $19.36
  • PDEX $51.93
  • Average True Range (ATR)
  • URGN 1.05
  • PDEX 2.61
  • MACD
  • URGN 0.27
  • PDEX 0.52
  • Stochastic Oscillator
  • URGN 92.16
  • PDEX 61.43

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

About PDEX Pro-Dex Inc.

Pro-Dex Inc is engaged in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used in the orthopedic, thoracic, and craniomaxillofacial (CMF) markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. Majority of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.

Share on Social Networks: